Announcements

Showing items 1411 - 1420 of 4313 stories.

WVU Cancer Institute first in state to implement new treatment for prostate cancer

Radiation oncologists at the WVU Cancer Institute are the first in the state to implement PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), a new treatment for metastatic prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC), which has spread to other parts of the body and has been resistant to other treatments.